AIMT - Aimmune reports positive AR101 data in peanut allergy study June, 04 2019 08:55 AM Aimmune Therapeutics Inc. Aimmune Therapeutics (NASDAQ:AIMT) announces results from ARC004, an open-label study of Phase 3 PALISADE trial.More news on: Aimmune Therapeutics, Inc., Healthcare stocks news, Read more ...